Some cardiovascular outcome trials, such as the LEADER trial with liraglutide and the SUSTAIN-6 trial with semaglutide, included fracture events as safety endpoints
November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
Rising demand for effective weight reduction strategies and improved glycemic control, especially in regions facing surging rates of metabolic disorders, is a key factor driving market expansion
PMID: 16529340 DOI: 10.1331/154434506775268698 Tushuizen ME et al (2006): Incretin mimetics as a novel therapeutic option for hepatic steatosis
Interestingly, GLP-2 administration leads to a reduction in PTH levels in people with an intact intestine, but not in those with short bowel syndrome, 63 indicating that an intact small intestine is required for GLP-2 mediated suppression of PTH secretion
For more information on Ro's Body Membership and full suite of GLP-1 options, visit Ro.co/weightloss About Ro Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the easiest, most effective care possible
